IONTAS starts cooperation with IGEM Therapeutic

| By | Cancer Drugs, Drug Development

IONTAS Limited (UK), a leader in the discovery and optimisation of fully human antibodies, will collaborate with IGEM Therapeutics (UK), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer.

The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study. IONTAS will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets.

IgE antibodies have been shown to permeate tumour tissue more effectively, exhibit enhanced effector functions and stimulate significantly greater levels of cytotoxicity and phagocytosis than IgG antibodies. IONTAS will apply its proprietary antibody discovery libraries and technologies to identify specific, high-affinity antibodies against two tumour-associated targets. Functional screening of IgE-formatted antibodies will be carried out to identify the most appropriate candidates for therapeutic development.

SOURCE: iontas
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.